between exposure and initial clinical symptoms, probably related to the disappearance of residual protective immunity in immigrants (1, 2) . Impaired immunity has also been linked to late malaria, implicating a chronic low-grade P. falciparum infection that becomes clinically evident in an immunocompromised person (3) . In addition, several cases of malaria without any travel history to a malariaendemic region have been described. A possible explanation for this type of malaria is exposure to an imported Anopheles spp. mosquito, referred to as airport, luggage, or container malaria (4). Transmission by indigenous anopheline mosquitoes when weather conditions are favorable has been reported in some European countries (5, 6) . Cases of P. falciparum malaria without any evidence of a mosquito bite have been reported and related to transfusion of parasitized erythrocytes, intravenous drug use, or accidental needlestick injuries (4).
We report a clinically atypical case of late P. falciparum malaria that may have been contracted by the bite of an anopheline mosquito captured in the luggage of the patient's visiting friend (7) . Unreported travel to a malaria-endemic region was possible but unlikely because our patient stayed illegally in Belgium and leaving the country would risk being repatriated to Guinea-Conakry. Indigenous malaria was excluded because he became ill during the winter, a time when proliferation of local Anopheles spp. in Belgium is diffi cult. The patient did not receive any recent blood transfusions and denied being an intravenous drug user, although this possibility cannot be excluded.
This type of malaria, also known as luggage or suitcase malaria, makes adequate and timely diagnosis difficult because a history of exposure to a possibly malaria-infected mosquito is apparently absent. Moreover, our patient had few classic symptoms or signs, such as high-grade fever, chills, or headaches; this pattern complicates diagnosis. This lack of typical malaria symptoms may be related to the fact that before coming to the hospital, the patient took ciprofl oxacin, which has in vitro activity against P. falciparum. Another possible reason is residual immunity to malaria, which was no longer protective but still capable of attenuating symptoms or signs of malaria. This fi nding implicates recrudescence of disease after a long period of asymptomatic infection with P. falciparum. Serologic analysis detected high levels of antibodies to Plasmodium spp., which suggests a chronic infection rather than a new one.
It is generally accepted that protective immunity wanes after several months of nonexposure. Support for this thesis is the frequency of clinical malaria in African adults who visit their families after a long stay in a country where the disease is not endemic. However, these cases might be caused by antigenic variation of P. falciparum in the area visited, which would enable the parasite to evade the host's immune response (8) . Residual immunologic memory against P. falciparum has been suggested, which would link persistent immunity with late recrudescence or with less severe or complicated disease in immigrants (2,9). Moreover, P. falciparum has been transmitted through blood transfusions from donors from malaria-endemic regions several years after exposure, which suggests long subpatent periods (10) .
This case highlights the problem of diagnosing P. falciparum malaria in patients without a recent travel history to malaria-endemic areas. In such cases, autochthonous malaria, whether transmitted by an imported or an indigenous mosquito or by infected blood cells or needles, should be excluded. Residual protective immunity, even after several years of nonexposure to P. falciparum, may explain persistent asymptomatic infection and late recrudescence of disease.
Linezolid-Resistant Staphylococcus cohnii, Greece
To the Editor: Since 2003, linezolid has typically been used to treat infections caused by multidrugresistant gram-positive cocci such as vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus (1) . In Greece, a major problem is nosocomial dissemination of vancomycin-resistant enterococci. Use of linezolid for the treatment of such infections led to the emergence of linezolid-vancomycin resistant E. faecium; however, linezolid resistance of staphylococci is still relatively low in this country (2) . We describe an outbreak caused by a linezolid-resistant S. cohnii in an intensive care unit (ICU) in Greece.
From July through October 2007, nonrepetitive coagulase-negative staphylococci that exhibited resistance to linezolid, were isolated from blood cultures from 4 separate patients hospitalized in the ICU at Sismanoglion General Hospital of Athens, a 450-bed tertiary care hospital. The ICU is a 10-bed, level II unit, comprising 2 rooms with 1 bed each and 2 rooms with 4 beds each. Each isolate was recovered in 2 of 2 blood culture sets per patient, indicating true bacteremia. The demographic and clinical information for the patients is described in the Table. The mean duration of time preceding linezolid therapy was 22 days.
Isolates were fi rst identifi ed to the species level by using an API Staph system (bioMérieux, la Balme les Grottes, France) and a molecular method based on the tuf gene followed by sequencing analysis (3). Susceptibility testing for various antimicrobial agents was performed by disk diffusion and using Clinical Laboratory Standards Institute criteria; susceptibilities were interpreted according to Institute guidelines (4). In addition, MICs to oxacillin, vancomycin, teicoplanin, quinupristin-dalfopristin, linezolid, daptomycin, and tigecycline were determined by Etest (AB Biodisk, Solna, Sweden) according to manufacturer's instructions. Resistance genes mecA, vat, vga, erm, aac(6´)-Ie+aph(2″), ant(4′)-Ia, and aph(3′)-IIIa, as markers for resistance to β-lactams, dalfopristin, macrolides, and aminoglycosides, were identifi ed by PCR as previously reported (5, 6) . The presence of G2576T in domain V of the 23S rRNA, which is mainly associated with linezolid resistance in clinical isolates, was detected by using PCR and digestion of the product with NheI (2). The number of mutated versus nonmutated alleles was determined as described by Pillai et al. (7) . In addition, isolates were examined for the presence of the cfr gene, which was found to be correlated with linezolid resistance in some coagulasenegative staphylococci and for mutations of ribosomal protein L4, L22 genes (8, 9) . Clonality of isolates was assessed by pulsed-fi eld gel electrophoresis (PFGE) after digestion of chromosomal DNA with SmaI (2).
The molecular method identifi ed the isolates as S. cohnii subsp. ureolyticus. The API Staph system has correctly identifi ed 2 of them; the re-
